Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23694066 | 1.00 | MAPT (0.55) | MAPTLMNAHTTDRD4ABCB1 | |
| SCHEMBL23694065 | 1.00 | MAPT (0.55) | MAPTLMNAHTTDRD4ABCB1 | |
| SCHEMBL23694447 | 0.90 | KDM4E (0.62) | MAPTLMNAHTTDRD4ABCB1 | |
| SCHEMBL23694445 | 0.90 | KDM4E (0.62) | MAPTLMNAHTTDRD4ABCB1 | |
| SCHEMBL23694446 | 0.90 | KDM4E (0.62) | MAPTLMNAHTTDRD4ABCB1 | |
| SCHEMBL23694639 | 0.89 | KDM4E (0.65) | MAPTLMNAHTTABCB1KDM4E | |
| SCHEMBL23694627 | 0.89 | KDM4E (0.65) | MAPTLMNAHTTABCB1KDM4E | |
| SCHEMBL23694628 | 0.89 | KDM4E (0.65) | MAPTLMNAHTTABCB1KDM4E | |
| SCHEMBL21094953 | 0.89 | CYP2D6 (0.64) | ABCB1KDM4ECYP2D6HTR2A | |
| SCHEMBL19912754 | 0.89 | CYP2D6 (0.64) | ABCB1KDM4ECYP2D6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | Exciva GmbH | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228508-A1 | COMPOSITIONS AND METHODS THEREOF | CYP21A2, CYP2C19, CYP2F1 | MAPT 3747/4885LMNA 1600/4885HTT 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.